|
Scritto da EurekAlert! - Infectious and Emerging Diseases
|
 (Aeras) The National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health, has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell. This is thee first time that NIH is leveraging its HIV/AIDS clinical trial networks to advance a tuberculosis vaccine candidate.
Fonte: EurekAlert! - Infectious and Emerging Diseases |
